Novavax: 1st shipment of R21/MatrixM malaria vaccine
The vaccine, licensed for use in children in malaria-endemic regions, aims to bridge the gap between demand and available doses, with distribution in Africa scheduled to begin in the coming weeks.
The vaccine combines the malaria-specific R21 antigen with Novavax's Matrix-M adjuvant to boost the immune response.
Results from Phase 3 clinical trials published in February 2024 demonstrated 'its safety and efficacy', says the laboratory.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction